CARY, N.C. and BRADENTON, Fla., May 20, 2026
Continuity Biosciences has announced the initiation of a Phase I first-in-human clinical trial evaluating its proprietary iontophoretic oncology platform (IOP) for the targeted delivery of gemcitabine in patients with pancreatic cancer. The study marks a major milestone for the clinical-stage biotechnology company as it advances precision drug delivery technologies designed to improve treatment effectiveness while reducing systemic toxicity in solid tumors.
The clinical study is now open for patient enrollment at major academic medical centers, including WVU Medicine J.W. Ruby Memorial Hospital and the University of Michigan Medical Center, reflecting growing clinical interest in localized drug delivery strategies for difficult-to-treat cancers. Researchers believe the platform may help overcome longstanding barriers limiting effective chemotherapy penetration into pancreatic tumors.
Pancreatic cancer remains among the deadliest forms of cancer worldwide, with five-year survival rates remaining critically low despite advances in systemic chemotherapy and targeted oncology therapies. Healthcare experts continue emphasizing the urgent need for innovative treatment approaches capable of improving therapeutic precision and reducing treatment-related complications.
Precision Drug Delivery Targets Pancreatic Tumors Directly
Continuity Biosciences’ investigational IOP platform was specifically developed to enable localized, controlled delivery of therapeutics directly into tumor tissue using iontophoretic technology. The approach aims to significantly increase drug concentration inside tumors while minimizing systemic exposure to chemotherapy agents.
Advertisement
Traditional systemic chemotherapy often struggles to penetrate pancreatic tumors effectively due to dense stromal tissue, abnormal vascular structures, and the highly resistant tumor microenvironment associated with pancreatic cancer. These biological barriers frequently limit treatment efficacy and contribute to severe systemic side effects that can reduce patient tolerance to therapy.
The company believes its precision delivery platform may improve the therapeutic index of existing oncology drugs by concentrating treatment where it is needed most while reducing off-target toxicity throughout the body. According to Continuity Biosciences, the platform was designed to support both currently approved therapies and future combination oncology strategies across multiple tumor types.
Researchers involved in the trial emphasized that targeted delivery methods could potentially improve outcomes for pancreatic cancer patients who currently face limited treatment options and poor long-term survival rates. Clinical investigators noted that safely increasing drug exposure directly within tumors may provide substantial therapeutic advantages compared with conventional systemic chemotherapy administration.
First-in-Human Study Evaluates Gemcitabine Delivery Technology
The Phase I clinical trial will evaluate safety, feasibility, and early therapeutic activity of gemcitabine delivered through the IOP platform. Gemcitabine has remained a foundational chemotherapy treatment for pancreatic cancer for many years, although systemic delivery limitations continue affecting clinical effectiveness.
Investigators from participating medical centers highlighted the importance of exploring new methods capable of improving delivery of established oncology drugs into resistant solid tumors. The study also represents a broader effort to modernize cancer treatment by integrating engineering innovation with pharmaceutical therapy.
According to clinicians involved in the program, localized intratumoral delivery could potentially reduce chemotherapy-related toxicities that frequently limit treatment duration and dosing intensity in advanced pancreatic cancer patients. Researchers additionally believe the platform may eventually support more effective use of immunotherapies, targeted therapies, and future precision oncology combinations.
Continuity Biosciences executives described the first-in-human study as a critical step toward transforming how cancer therapies are administered across multiple solid tumor indications. The company believes its technology could establish a new treatment paradigm centered around spatially precise drug delivery rather than reliance solely on systemic drug exposure.
Precision Oncology Platforms Continue Expanding Across Cancer Care
The launch of the pancreatic cancer trial reflects broader momentum within the oncology sector toward precision medicine technologies designed to personalize and optimize therapeutic delivery. Advanced drug delivery systems are increasingly being explored as pharmaceutical developers seek to improve efficacy of existing cancer therapies while minimizing toxicity burdens.
Beyond pancreatic cancer, Continuity Biosciences confirmed ongoing exploration of its IOP platform in additional oncology applications, including localized delivery of carboplatin for oral head and neck cancers. The company also indicated that its broader technology platform may have future applications beyond oncology, including endocrinology and other disease areas requiring highly targeted therapeutic administration.
Industry analysts believe precision drug delivery technologies could become increasingly important in next-generation oncology care as researchers continue developing more complex therapeutic combinations requiring controlled spatial delivery and improved tumor penetration.
The first-in-human clinical trial positions Continuity Biosciences among a growing number of biotechnology innovators focused on enhancing treatment effectiveness through advanced therapeutic delivery engineering. Experts expect the results of the Phase I study to be closely monitored as the oncology industry continues pursuing safer and more precise cancer treatment strategies worldwide.
Source: Continuity Biosciences press release
